| 酪氨酸激酶抑制剂帕唑帕尼的药理与临床研究 |
| |
| 引用本文： | 郑宇静,姜文亮,王志宏,刘治军,封宇飞.酪氨酸激酶抑制剂帕唑帕尼的药理与临床研究[J].中国新药杂志,2011(12). |
| |
| 作者姓名： | 郑宇静 姜文亮 王志宏 刘治军 封宇飞 |
| |
| 作者单位： | 卫生部北京医院药学部; |
| |
| 摘 要： | 帕唑帕尼为一种新型多靶点酪氨酸激酶抑制剂,临床用于治疗肾细胞癌。该药在临床前和临床研究中表现出了较强的抗肿瘤活性,且耐受性较好。文中通过文献检索对该药的药理作用、药动学、临床研究及安全性等进行了综述。
|
| 关 键 词： | 帕唑帕尼 酪氨酸激酶抑制剂 肾细胞癌 |
Progress in pharmacological and clinical studies of the tyrosine kinase inhibitor pazopanib |
| |
| ZHENG Yu-jing,JIANG Wen-liang,WANG Zhi-hong,LIU Zhi-jun,FENG Yu-fei.Progress in pharmacological and clinical studies of the tyrosine kinase inhibitor pazopanib[J].Chinese Journal of New Drugs,2011(12). |
| |
| Authors: | ZHENG Yu-jing JIANG Wen-liang WANG Zhi-hong LIU Zhi-jun FENG Yu-fei |
| |
| Institution: | ZHENG Yu-jing,JIANG Wen-liang,WANG Zhi-hong,LIU Zhi-jun,FENG Yu-fei (Department of Pharmacy,Beijing Hospital of the Ministry of Health,Beijing 100730,China) |
| |
| Abstract: | Pazopanib is a novel multi-targeted receptor tyrosine kinase inhibitor.It was proved to be used in the treatment of renal cell carcinoma.The preclinical and clinical researches have demonstrated that pazopanib has potent antitumor effects and is well tolerated.The mechanism of action,pharmacokinetics,clinical studies,and safety were reviewed in this paper. |
| |
| Keywords: | pazopanib tyrosine kinase inhibitor renal cell carcinoma(RCC) |
| 本文献已被 CNKI 等数据库收录！ |
|
